Applications and mechanism of some clinical common medications used as anti-cancer therapy sensitizer

doi:10.3760/cma.j.issn.1673422X.2014.09.004

Abstract

Abstract: A number of medications have been proved to be able to either improve the antitumor effect of chemotherapeutics and molecular targeted drugs or reverse the resistance of tumors to chemotherapeutics and molecular targeted drugs, which are not traditionally used as anticancer drugs. Especially for late-stage tumors after multiple treatments, these agents are good alternatives when used independently or in combination with chemotherapeutics and molecular targeted drugs. These drugs include proton modulators, hypoglycemic agents and cardiovascular agents, etc.

Key words: Antineoplastic agents, Proton pump inhibitors, Sodium bicarbonate, Hypoglycemic agents, Cardiovascular agents

Li Rutian, Qian Xiaoping, Liu Baorui. Applications and mechanism of some clinical common medications used as anti-cancer therapy sensitizer[J]. Journal of International Oncology, 2014, 41(8): 651-655.

References

［1］ Webb BA, Chimenti M, Jacobson MP, et al. Dysregulated pH: a perfect storm for cancer progression［J］. Nat Rev Cancer, 2011, 11(9): 671-677. ［2］Raghunand N, Gillies RJ. pH and chemotherapy［J］. Novartis Found Symp, 2001, 240: 199-211, 265-268. ［3］Li R, Xie L, Zhu Z, et al. Reversion of pHinduced physiological drug resistance: a novel function of copolymeric nanoparticles［J］. PLoS One, 2011, 6(9): e24172. ［4］Spugnini E, Citro G, Fais S. Proton pump inhibitors as anti vacuolarATPases drugs: a novel anticancer strategy［J］. J Exp Clin Cancer Res, 2010, 29: 44. ［5］李茹恬, 钱晓萍, 刘宝瑞. 恶性肿瘤pH依赖性生理性耐药及其对策［J］. 肿瘤, 2012, 32(5): 384-388. ［6］ Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs［J］. J Natl Cancer Inst, 2004, 96(22): 1702-1713. ［7］ Raghunand N, He X, van Sluis R, et al. Enhancement of chemotherapy by manipulation of tumour pH［J］. Br J Cancer, 1999, 80(7): 1005-1011. ［8］ Robey F, Baggett K, Kirkpatrick D, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases［J］. Cancer Res, 2009, 69(6): 2260-2268. ［9］ Robey F, Martin K. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer［J］. BMC Cancer, 2011, 11: 235. ［10］ Wong P, Lee C, Tannock F. Reduction of intracellular pH as a strategy to enhance the pHdependent cytotoxic effects of melphalan for human breast cancer cells［J］. Clin Cancer Res, 2005, 11(9): 3553-3557. ［11］ Li D. Metformin as an antitumor agent in cancer prevention and treatment［J］. J Diabetes, 2011, 3(4): 320-327. ［12］ Jalving M, Gietema A, Lefrandt D, et al. Metformin: taking away the candy for cancer?［J］. Eur J Cancer, 2010, 46(13): 2369-2380. ［13］ Hersey P, Watts N, Zhang D, et al. Metabolic approaches to treatment of melanoma［J］. Clin Cancer Res, 2009, 15(21): 6490-6494. ［14］ GonzalezAngulo M, MericBernstam F. Metformin: a therapeutic opportunity in breast cancer［J］. Clin Cancer Res, 2010, 16(6): 1695-1700. ［15］ VazquezMartin A, OliverasFerraros C, del Barco S, et al. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy［J］. Ann Oncol, 2009, 20(3): 592-595. ［16］ Hirsch A, Iliopoulos D, Tsichlis N, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission［J］. Cancer Res, 2009, 69(19): 7507-7511. ［17］ AyreG, Garcia D, Garcia J. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer［J］. Med Hypotheses, 2000, 55(4): 330-334. ［18］ Damyanov C, Radoslavova M, Gavrilov V, et al. Low dose chemotherapy in combination with insulin for the treatment of advanced metastatic tumors. Preliminary experience［J］. J BUON, 2009, 14(4): 711-715. ［19］ Vaklavas C, Chatzizisis S, Tsimberidou M. Common cardiovascular medications in cancer therapeutics［J］. Pharmacol Ther, 2011, 130(2): 177-190. ［20］ Kawazoe N, Aiuchi T, Masuda Y, et al. Induction of apoptosis by bufalin in human tumor cells is associated with a change of intracellular concentration of Na+ ions［J］. J Biochem, 1999, 126(2): 278-286. ［21］ Bielawski K, Winnicka K, Bielawska A. Inhibition of DNA topoisomerases Ⅰ and Ⅱ, and growth inhibition of breast cancer MCF7 cells by ouabain, digoxin and proscillaridin A［J］. Biol Pharm Bull, 2006, 29(7): 1493-1497. ［22］ Manna K, Sreenivasan Y, Sarkar A. Cardiac glycoside inhibits IL8induced biological responses by downregulating IL8 receptors through altering membrane fluidity［J］. J Cell Physiol, 2006, 207(1): 195-207. ［23］ Zhang H, Qian Z, Tan S, et al. Digoxin and other cardiac glycosides inhibit HIF1alpha synthesis and block tumor growth［J］. Proc Natl Acad Sci USA, 2008, 105(50): 19579-19586. ［24］ Beheshti R, Lau S, Hurren R, et al. Inhibition of the sodium/potassium ATPase impairs Nglycan expression and function［J］. Cancer Res, 2008, 68(16): 6688-6697. ［25］ Mekhail T, Kaur H, Ganapathi R, et al. Phase 1 trial of Anvirzel in patients with refractory solid tumors［J］. Invest New Drugs, 2006, 24(5): 423-427. ［26］ Vallianou N, Kostantinou A, Kougias M, et al. Statins and cancer［J］. Anticancer Agents Med Chem, 2014, 14(5): 706-712. ［27］ Rao S, Porter C, Chen X, et al. Lovastatinmediated G1 arrestis through inhibition of the proteasome, independent of hydroxymethylglutarylCoA reductase［J］. Proc Natl Acad Sci USA, 1999, 96(14): 7797-7802. ［28］ Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance［J］. Nat Rev Cancer, 2005, 5(4): 275-284. ［29］ Belpomme D, Gauthier S, PujadeLauraine E, et al. Verapamil increases the survival of patients with anthracyclineresistant metastatic breast carcinoma［J］. Ann Oncol, 2000, 11(11): 1471-1476. ［30］沈洁, 刘宝瑞. 硝酸甘油提高晚期非小细胞肺癌化疗疗效研究进展［J］. 肿瘤防治研究, 2011, 38(5): 594-596. ［31］ Yasuda H, Yamaya M, Nakayama K, et al. Randomized phase Ⅱ trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage ⅢB/Ⅳ nonsmallcell lung cancer［J］. J Clin Oncol, 2006, 24(4): 688-694.

[1]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili. Research progress of avermectins in anti-tumor [J]. Journal of International Oncology, 2022, 49(6): 353-356.
[3]	Liu Chaoxing, Yan Xuebing, Yang Mengxue, Tong Jiandong, Mao Haiyan. Effects of proton pump inhibitors on outcomes for advanced solid tumor patients treated with immune checkpoint inhibitors [J]. Journal of International Oncology, 2022, 49(1): 26-32.
[4]	Wang Shuang, Tang Yunyun, Yue Qi. New progress in antitumor research of non-psychoactive cannabidiol [J]. Journal of International Oncology, 2020, 47(10): 619-623.
[5]	Yi Lin, Qiu Shi. Anti-tumor effect and mechanisms of shikonin on gliomas [J]. Journal of International Oncology, 2019, 46(8): 489-491.
[6]	Liang Jing1,3, Han Sha2, Yao Jing3, Kong Qingsheng2. Effect of histone deacetylase and its inhibitor on tumor [J]. Journal of International Oncology, 2019, 46(4): 235-238.
[7]	Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong. Molecular targeted therapy for advanced kidney cancer [J]. Journal of International Oncology, 2019, 46(12): 705-710.
[8]	Wang Gang, Wang Huangzhen, Xue Ting. Effect of oxaliplatin induced autophagy on drug resistance of SGC7901 gastric cancer cells [J]. Journal of International Oncology, 2018, 45(8): 513-518.
[9]	Ling Xiaofei, Xu Ke, Shao Hua, Wang Cuijuan. Anticancer mechanism and application of curcumin analog EF24 [J]. Journal of International Oncology, 2018, 45(3): 172-175.
[10]	Chen Gang, Zhuang Fangcheng. High mobility group box 1 and its role in cervical cancer [J]. Journal of International Oncology, 2017, 44(3): 235-238.
[11]	Dong Yi, Wei Yuehua, Hu Weiguo, Song Qibin. Therapy for non-small cell lung cancer patients with solitary bone metastases [J]. Journal of International Oncology, 2017, 44(1): 60-62.
[12]	DU Ji-Hui, ZHANG Hou-De, WEI Jing, WANG Lei, SUN Ting-Ji. Correlation of peroxisome pathway reactive oxygen species oxidative stress gene and its correlation with the antitumor sensitivity of artesunate against pancreatic cancer [J]. Journal of International Oncology, 2016, 43(7): 503-507.
[13]	ZHANG Wen-Dian, XU Zu-Min, YU Zhong-Hua. Antitumor mechanism of gambogic acid [J]. Journal of International Oncology, 2016, 43(4): 293-295.
[14]	CHEN Zhi-Da, ZENG Wen-Rong, LIN Bin, WU Xin-Yu, WU Jin. Voltagegated potassium channel Kv1.5 and cancer [J]. Journal of International Oncology, 2016, 43(2): 130-.
[15]	XIN Zhong-Yang, WANG Bao-Cheng, WANG Jun. Antitumor effect and its molecular mechanism of artemisinin and its derivatives [J]. Journal of International Oncology, 2016, 43(12): 927-929.